AzTrials
AzTrials

COPDPhase 3NCT00557115

Early Pulmonary Rehabilitation Following Acute COPD Exacerbation

A Phase 3 study testing Early pulmonary rehabilitation (EPR) in people with COPD, run by King's College Hospital NHS Trust at 3 sites in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The principal aim of the study is to evaluate whether attendance at an exercise training and education programme (known as pulmonary rehabilitation) shortly following hospital discharge can lead to a reduction in exacerbations and improvement in exercise capacity and quality of life in patients with chronic… Read more about this study

Who is it for?
Ages 40 to 90 years
Conditions the study is for
COPD
What is being tested?
Early pulmonary rehabilitation (EPR)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
3 sitesUnited Kingdom
Study dates
Jan 2006to 16 Apr 2008
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All patients admitted to King's College Hospital with a clinical diagnosis of acute exacerbation of COPD. Patients with radiological and microbiological evidence of pneumonia with co-existing COPD will also be included.

Who cannot join

  • Significant co-morbidity that could limit exercise training \& testing: Patients unable to walk due to a comorbid neuromuscular or rheumatological condition; patients with severe sensory and cognitive impairment; patients with unstable angina or aortic valve disease in which exercise could be dangerous.
  • Attendance at a pulmonary rehabilitation programme in the preceding year.

Trial locations and contacts

3 sites in 1 country.

United Kingdom3 sites
  • Basildon University Hospital

    Basildon, Essex

  • St Thomas' Hospital

    London, SE1 7EH

  • King's College Hospital

    London, SE5 9RJ

Other trials in United Kingdom

About this study

Official title: Early Pulmonary Rehabilitation (PR) Following Hospitalisation For Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

The principal aim of the study is to evaluate whether attendance at an exercise training and education programme (known as pulmonary rehabilitation) shortly following hospital discharge can lead to a reduction in exacerbations and improvement in exercise capacity and quality of life in patients with chronic obstructive pulmonary disease.

Read the detailed description

Background:

Chronic obstructive pulmonary disease (COPD), also sometimes known as chronic asthma, bronchitis or emphysema, is an important health problem. Many people with COPD are admitted into hospital with a worsening of their symptoms, known as an exacerbation. Hospitalisations for acute exacerbations of chronic obstructive pulmonary disease (COPD) are a massive burden to the NHS. Over the past decade, these hospitalizations have increased by 50%, and annual hospital costs for COPD in the UK amount to more than £587 million. After being discharged, some people fail to cope very well due to a variety of reasons. A prolonged stay in hospital may lead to muscle weakness, particularly of the leg muscles [1], a loss of confidence in performing everyday activities, and increased anxiety [2]. A high proportion of these patients are re-admitted to hospital following discharge. The aim of the study is to assess whether attendance at an exercise training and education programme shortly following discharge can firstly, improve exercise capacity and quality of life, and secondly, reduce the use of health resources and costs to the NHS.

It is known that an exercise training and education programme known as Pulmonary Rehabilitation is beneficial to stable patients with COPD by reducing breathlessness, increasing exercise capacity and improving quality of life. We have recently performed a pilot study that has shown that early Pulmonary Rehabilitation has considerable short-term benefits in patients with COPD who have been recently discharged following a hospital admission for worsening of their symptoms [3]. We hypothesise that these benefits are long-lasting, and may reduce use of healthcare resources and costs to the NHS.

References:

  1. Spruit, M.A., et al., Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax, 2003. 58(9): p. 752-6.
  2. Seemungal, T.A., et al., Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 1998. 157(5 Pt 1): p. 1418-22.
  3. Man, W.D., et al., Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. BMJ, 2004. 329(7476): p. 1209.

Description of Study:

Based on the results of our pilot study [1], we hypothesise that early pulmonary rehabilitation (EPR) leads to long term improvements in exercise capacity, quality of life, use \& resulting costs of healthcare resources, peripheral muscle strength and daily activity levels. The null hypothesis is that EPR does not lead to a significant difference in outcome when compared to usual care (UC).

EXPERIMENTAL DESIGN AND METHODS: This is a prospective randomised controlled clinical trial of EPR vs. usual care.By using a control group, statistically significant differences in outcome can be attributed to EPR. No treatment considered to be part of routine care is being withheld from the UC group.

Patients: Patients studied will be those with an acute exacerbation of COPD deemed sufficiently unwell by the duty medical registrar to warrant hospital admission. Exclusion criteria will include significant co-morbidity that could limit exercise training, and attendance at a pulmonary rehabilitation programme in the preceding year. In-patient treatment will include standard therapy (nebulised bronchodilators, oxygen, non-invasive ventilation (if required), antibiotics and a 1-2 week course of oral prednisolone 30-40mg daily). On hospital discharge, patients will be allocated either to the early pulmonary rehabilitation (EPR) group (within 7 days of hospital discharge) or usual care (UC) i.e. routine outpatient and primary-care follow-up.

PROTOCOL: In the 48 hours before planned hospital discharge, the following measurements will be made in all patients:

  1. Pulmonary function tests, including ear-lobe blood gases, spirometry, lung volumes, and transfer factor.
  2. Anthropometric data, including height, weight, body mass index, lean body mass (as measured by bio-electrical impedance)
  3. Field exercise capacity as measured by the incremental shuttle walk, a standard externally paced, incremental, maximal,corridor-walking test [2].
  4. Disease-specific and generic health status, as measured by the Chronic Respiratory Diseases Questionnaire (CRDQ) [3],St George's Respiratory Questionnaire (SGRQ) [4]. Interviews will take place in the lung function department at King's College Hospital.
  5. Cardiopulmonary exercise testing in a subset of voulnteers, with measurements of VO2, and VCO2 and lactic acid.
  6. Non-volitional and volitional quadriceps strength: twitch quadriceps tension following supramaximal stimulation of femoral nerve and maximum isometric voluntary contraction. This is a painless supramaximal method of assessing quadriceps strength and fatigue [5] [6].
  7. Endurance walking capacity (endurance shuttle walk)
  8. Health resource usage (see later). The EuroQol (EQ-5D) instrument [7] will be used as the main measure of health-related quality-of-life in the economic evaluation.

The measurements made at baseline will be repeated at 3 and 12 months. Of note, as this study is a prospective longitudinal study, patients will be familiarised with the exercise tests in the days before discharge to minimise learning effect. Verbal encouragement during exercise testing will be standardised to avoid researcher effects. The assessor will be blinded to the subject's intervention. However owing to the nature of the intervention, it will not be possible to blind the subjects to their intervention.

RANDOMISATION: At discharge, patients will be allocated to either a hospital outpatient exercise rehabilitation programme, or usual care. Due to the numbers to be studied, allocation of treatments using the minimisation method will be used to ensure comparable groups. The following factors will be taken into account:

  1. Age (above and below 70)
  2. Gender (male/female)
  3. Hospital Discharge incremental shuttle walk distance (more or less than 100 metres).
  4. Length of Hospital Admission (more or less than 7 days)
  5. FEV1 more or less than 30% predicted

INTERVENTION: Patients allocated to the EPR group will attend a pulmonary rehabilitation programme within 7 days of hospital discharge. This will consist of two sessions a week for 8 weeks, and will be supervised by a multi-disciplinary team consisting of physiotherapists, occupational therapists, nurses and dieticians as well as the clinical research fellow funded by the proposed grant. Each session consists of 60 minutes exercise, made up of aerobic walking and cycling exercise plus lower and upper limb strength and endurance exercise, and 1 hour of discussion focusing on psychosocial and lifestyle issues, with a particular emphasis on nutrition and domestic activity. The EPR group will be also be given an individualised home exercise programme, encouraging daily exercise. The UC group will receive usual outpatient and primary care follow-up.

HEALTH ECONOMICS: The EuroQol (EQ-5D) instrument will be used as the main measure of health-related quality-of-life in the economic evaluation [9]. It has been developed by a collaborative group of European researchers as a preference-based index, suitable for the calculation of QALYs. The EQ-5D is one of two instruments currently recommended for use in economic evaluations [8]. Information on patients' use of health services will be collected by a review of hospital notes, patient recall and a home diary issued to all study participants. The resources included will be: hospital admissions, inpatient days, ITU days, outpatient consultations, A\&E attendances, and primary care surgery and home visits.

SAMPLE SIZE: Our preliminary pilot study was powered to detect a 50-metre difference in incremental shuttle walk at the 5% significance level with 90% power. Based on the health resource usage data collected from this pilot study, to detect a 50% reduction in hospital readmission rate at the 5% significance level with 80% power would require a minimum of 60 patients (30 in each group). We propose to study 80 patients in this study

References:

  1. Man, W.D., et al., Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. BMJ, 2004. 329(7476): p. 1209.
  2. Singh, S.J., et al., Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax, 1992. 47(12): p. 1019-24.
  3. Guyatt, G.H., et al., A measure of quality of life for clinical trials in chronic lung disease. Thorax, 1987. 42(10): p. 773-8.
  4. Jones, P.W., et al., A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis, 1992. 145(6): p. 1321-7.
  5. Man, W.D., et al., Non-volitional assessment of skeletal muscle strength in patients with chronic obstructive pulmonary disease. Thorax, 2003. 58(8): p. 665-9.
  6. Polkey, M.I., et al., Quadriceps strength and fatigue assessed by magnetic stimulation of the femoral nerve in man. Muscle Nerve, 1996. 19(5): p. 549-55.
  7. Brooks, R., EuroQol: the current state of play. Health Policy, 1996. 37(1): p. 53-72.
  8. Brazier, J., M. Deverill, and C. Green, A review of the use of health status measures in economic evaluation. J Health Serv Res Policy, 1999. 4(3): p. 174-84.
Conditions
COPD
Being tested
Early pulmonary rehabilitation (EPR)
Keywords
Quality of life, Quadriceps, Muscle, Exacerbation
Medical subject headings
Pulmonary Disease, Chronic Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Early pulmonary rehabilitation (EPR)Other

    Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.

Study groups in NCT00557115
Study groupRoleWhat they receive
Usual CareNo interventionUsual Care (UC): usual follow up care post acute COPD exacerbation
EPRExperimentalEarly pulmonary rehabilitation (EPR): pulmonary rehabilitation commenced within 1-week of hospital discharge from an acute COPD exacerbation
Receives: Other: Early pulmonary rehabilitation (EPR)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Non-outpatient COPD related hospital attendance (A+E attendance, inpatient admission or death)

    Measured: 3-months

Secondary outcomes (5)
  1. Disease specific quality of life (CRDQ and SGRQ)

    Measured: 3 months and 1-year

  2. Maximal walking capacity (ISW)and endurance walking capacity (ESW)

    Measured: 3-months and 1-year

  3. Weight and fat free mass (electrical bioimpedance)

    Measured: 3-months and 1-year

  4. Quadriceps muscle strength (volitional and non-volitional)

    Measured: 3-months and 1-year

  5. Cost-effectiveness (Index derived from EQ-5D)

    Measured: 3-months and 1-year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Nov 2007 (estimated)
  2. Study startJan 2006
  3. Primary completion15 Apr 2008
  4. Study completion16 Apr 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00557115
Sponsor's protocol ID
05/Q0703/093
Other IDs
BLF PO4/8
Status last verified
Nov 2007
First submitted
9 Nov 2007
Last updated
24 Dec 2020
Results posted
No
Data monitoring committee
No

Publications

  • Seymour JM, Moore L, Jolley CJ, Ward K, Creasey J, Steier JS, Yung B, Man WD, Hart N, Polkey MI, Moxham J. Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax. 2010 May;65(5):423-8. doi: 10.1136/thx.2009.124164.

    PubMed 20435864

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Early pulmonary rehabilitation (EPR) in people with COPD, run by King's College Hospital NHS Trust at 3 sites in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Non-outpatient COPD related hospital attendance (A+E attendance, inpatient admission or death) (time frame: 3-months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00557115, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in